Group therapy for mental health in people with neurological disorders
Acceptance and Commitment Therapy- Based Group Therapy for Mental Health in Neurological Disorders
NA · Bielefeld University · NCT06897553
This study is testing if group therapy using Acceptance and Commitment Therapy can help improve mental health for people with neurological disorders, including those recovering from COVID-19.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 44 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bielefeld University (other) |
| Locations | 1 site (Bielefeld) |
| Trial ID | NCT06897553 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of Acceptance and Commitment Therapy (ACT) in improving mental health outcomes for individuals with various neurological disorders, including those recovering from COVID-19. Participants will engage in eight weekly group therapy sessions, each lasting 100 minutes, focusing on enhancing psychological flexibility and addressing issues such as depression, anxiety, and stress. The study will also explore the relationship between executive functions and the success of therapy, particularly how cognitive abilities may influence social participation and mental health improvements. The research builds on previous findings that indicated the feasibility and potential benefits of ACT for stroke survivors.
Who should consider this trial
Good fit: Ideal candidates include individuals with neurological disorders who exhibit symptoms of depression, anxiety, or stress and have sufficient cognitive and language abilities.
Not a fit: Patients with severe mental disorders, such as dementia or psychosis, or those currently undergoing other forms of psychotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could significantly improve mental health and quality of life for patients with neurological disorders.
How similar studies have performed: Previous studies have shown promising results for ACT in similar populations, indicating potential efficacy for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Value above a cut-off of the DASS-21 subscales (depression \> 10, anxiety \> 6, and stress \> 10) * Sufficient cognition and language ability (clinical rating) * Sufficient therapy motivation (clinical rating) Exclusion Criteria: * Behavioral disorders (e.g., high irritability or apathy in clinical rating) * Other severe mental disorder (dementia, psychosis, personality disorders, intellectual disability) * Simultaneous psychotherapy or neuropsychological therapy
Where this trial is running
Bielefeld
- Neuropsychologische Hochschulambulanz Bielefeld — Bielefeld, Germany (RECRUITING)
Study contacts
- Study coordinator: Simon Ladwig, PhD
- Email: simon.ladwig@uni-bielefeld.de
- Phone: +49 (0) 521 106 67533
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neurological Disorders, Mental Health, Executive Function, Depression/Anxiety, Stress, Brain Injury, Post-COVID, Acceptance and Commitment Therapy